{"id":"https://openalex.org/W4390339727","doi":"https://doi.org/10.18565/pharmateca.2023.13.42-46","title":"Results of comparison of the effectiveness of adalimumab and ixekizumab in the treatment of psoriasis","display_name":"Results of comparison of the effectiveness of adalimumab and ixekizumab in the treatment of psoriasis","publication_year":2023,"publication_date":"2023-12-27","ids":{"openalex":"https://openalex.org/W4390339727","doi":"https://doi.org/10.18565/pharmateca.2023.13.42-46"},"language":"en","primary_location":{"id":"doi:10.18565/pharmateca.2023.13.42-46","doi":"https://doi.org/10.18565/pharmateca.2023.13.42-46","is_oa":false,"landing_page_url":"https://doi.org/10.18565/pharmateca.2023.13.42-46","pdf_url":null,"source":{"id":"https://openalex.org/S4210167942","display_name":"\u0424\u0430\u0440\u043c\u0430\u0442\u0435\u043a\u0430","issn_l":"2073-4034","issn":["2073-4034","2414-9128"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["russia-white-list-3"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmateca","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5093601472","display_name":"Sh.Kh.R. Sarsur Sarsur","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sh.Kh.R. Sarsur Sarsur","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5012829095","display_name":"\u041d. \u0421. \u0420\u0443\u0434\u043d\u0435\u0432\u0430","orcid":"https://orcid.org/0000-0001-9638-2290","observed_orcids":["https://orcid.org/0000-0001-9638-2290","https://orcid.org/0000-0002-0621-5518"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N.S. Rudneva Rudneva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"13_2023","issue":null,"first_page":"42","last_page":"46"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.9800000190734863},{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":1.0},{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.9900000095367432},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.7099999785423279},{"id":"https://openalex.org/keywords/il-17-inhibitors","display_name":"IL-17 inhibitors","score":0.9139999747276306},{"id":"https://openalex.org/keywords/treatment-effectiveness-comparison","display_name":"treatment effectiveness comparison","score":0.5809999704360962}],"concepts":[{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.985967755317688},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.8515399694442749},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.8087478876113892},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6862423419952393},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.41343021392822266},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25190573930740356},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.2100594937801361},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.08683943748474121},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.06668761372566223}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.18565/pharmateca.2023.13.42-46","doi":"https://doi.org/10.18565/pharmateca.2023.13.42-46","is_oa":false,"landing_page_url":"https://doi.org/10.18565/pharmateca.2023.13.42-46","pdf_url":null,"source":{"id":"https://openalex.org/S4210167942","display_name":"\u0424\u0430\u0440\u043c\u0430\u0442\u0435\u043a\u0430","issn_l":"2073-4034","issn":["2073-4034","2414-9128"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["russia-white-list-3"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmateca","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4238821550","https://openalex.org/W4246555606","https://openalex.org/W2948018050","https://openalex.org/W4235848745","https://openalex.org/W2418808667","https://openalex.org/W2600720423","https://openalex.org/W2980340587","https://openalex.org/W2947107744","https://openalex.org/W2000300659","https://openalex.org/W4386122231"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2023-12-29T00:00:00"}